5. INTRODUCTION

Background Information

The investigational product is CuretALL, which is a compound created by Pharma Corporation for the purpose of relieving severe allergic symptoms and can be used by patients suffering from chronic asthma. The chemical structure for the compound is as follows:

Chemical Structure of CuretALL

Nonclinical Summary

The findings from 12 nonclinical studies (Appendices 2.1 through 2.12) indicate acceptable results for development of CuretALL for the indications stated.

Potential Risks and Benefits

There are no known potential risks to humans based on studies to date. There is a potential benefit to patients suffering from chronic asthma who are also suffering from allergies.

Route of Administration, Dosage, Dosage Regimen and Treatment Periods

We believe the study will support the premise that a 5mg tablet taken orally upon rising will deliver the most efficacious dosage to study subjects.